Danish pharma large Novo Nordisk teased promising early-stage trial outcomes of its experimental weight loss pill amycretin, sending the business’s stock surging.GLP-one agonist medications, normally called GLP-1s, are injectable drugs that get the job done by mimicking the GLP-1 hormone that the small intestine can make in reaction to foods, for